Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.68 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.68 |
| ▸ | ITGB7 | P26010 | 20/20 | 0.68 |
| ▸ | ITGAV | P06756 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926949 | 0.92 | ITGB1 (0.80) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL13671316 | 0.92 | ITGB1 (0.80) | ITGB1ITGA4ITGB7ITGAV | |
| Hydrochloric Acid SCHEMBL2961791 | 0.91 | ITGB1 (0.79) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2957798 | 0.91 | ITGB1 (0.78) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL3044769 | 0.87 | ITGB1 (0.57) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2852300 | 0.86 | ITGB1 (0.73) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2852304 | 0.86 | ITGB1 (0.73) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2951232 | 0.86 | ITGB1 (0.88) | ITGB1ITGA4ITGB7ITGAV | |
| SCHEMBL2608720 | 0.86 | ITGB1 (0.67) | ITGB1ITGA4ITGB7 | |
| SCHEMBL2951581 | 0.85 | ITGB1 (0.88) | ITGB1ITGA4ITGB7ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8269009-B2 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ELAN PHARMACEUTICALS, INC. | 2009-12-17 | — | — | US | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605166-B2 | Synergistic mixture of methotrexate and integrin antigen or antibody | ELAN PHARMACEUTICALS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1635822-A4 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARM INC (US) | 2009-06-24 | — | — | EP | disclosed |
| EP-1507775-B1 | HETEROCYCLIC COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY ALPHA4 INTEGRINS | ELAN PHARM INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7427628-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427628-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427628-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7026328-B2 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1635871-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1635822-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2006-01-05 | — | — | US | disclosed |
| WO-2005097162-A2 | STEROID SPARING AGENTS AND THEIR USE | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050119290-A1 | N-(2-[N',N'-diethylamino]-5-[N''-(4-fluorophenylsulfonyl)-N''-propargylamino]pyrimidin-4-yl)-4'-(pyrrolidin-1-ylcarbonyloxy)-L-phenylalanine; antiinflammatory, antiarthritic agents | ELAN PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2005000244-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000246-A2 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | ELAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040138243-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4integrins | WYETH | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312353-A1 | Methods and compositions for treating liquid tumors | ITGB4, ITGA4, ITGB3 | ITGB1 4/4885ITGA4 2/4885ITGB7 13/4885 |
| US-20060004019-A1 | Steroid sparing agents and methods of using same | IL5, FCER2, CD40 | ITGB1 305/4885ITGA4 298/4885ITGB7 485/4885 |
| US-20050119290-A1 | N-(2-[N',N'-diethylamino]-5-[N''-(4-fluorophenylsulfonyl)-N''-propargylamino]pyrimidin-4-yl)-4'-(pyrrolidin-1-ylcarbonyloxy)-L-phenylalanine; antiinflammatory, antiarthritic agents | VCAM1, ICAM1, ITGB4 | ITGB1 28/4885ITGA4 5/4885ITGB7 137/4885 |
| US-20040138243-A1 | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4integrins | VCAM1, ICAM1, ITGB4 | ITGB1 15/4885ITGA4 4/4885ITGB7 49/4885 |
| US-20050074451-A1 | Methods and compositions for treating rheumatoid arthritis | VCAM1, ICAM1, ITGA4 | ITGB1 8/4885ITGA4 3/4885ITGB7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.